Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy after Complete Endoscopic Management of Upper Tract Urothelial Carcinoma

Craig Labbate; Solomon Woldu; Katie Murray; Kyle Rose; Wade Sexton; Isamu Tachibana; Hristov Kaimakliotis; Joseph Jacob; Rian Dickstein; Jennifer Linehan; Alan Nieder; Marc Bjurlin; Mitchell Humphreys; Saum Ghodoussipor; Marcus Quek; Michael O'Donnell; Brian Eisner; Adam Feldman; Yair Lotan; Surena F. Matin

Article

Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy after Complete Endoscopic Management of Upper Tract Urothelial Carcinoma

Journal of Urology

DOI: 10.1097/JU.0000000000003185

17Citations

7Readers

Get full text

Author supplied keywords

Cite

CITATION STYLE

APA

Labbate, C., Woldu, S., Murray, K., Rose, K., Sexton, W., Tachibana, I., … Matin, S. F. (2023, May 1). Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy after Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. Journal of Urology. Wolters Kluwer Health. https://doi.org/10.1097/JU.0000000000003185

Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy after Complete Endoscopic Management of Upper Tract Urothelial Carcinoma

Author supplied keywords

Cite

Register to see more suggestions